PubMed Health⌕ Search

Biomedical subjects

T Koeda

Publications and source records attributed to T Koeda.

At least 109 records · Page 6Linked to original sources
PubMed1985

Lack of mutagenicity of fasciolicides.

Six fasciolicides, bithionol, bromofenofos, DS-6, nitroxynil, oxyclozanide and tribromsalan, were tested for mutagenicity in the Salmonella reverse mutation test using S. typhimurium tester strains TA100, TA98, TA1535, TA1537 and TA1538 and the micronucleus test in mice. None of the fasciolicides increased the number of revertant colonies in any tester strain in the presence and absence of S9 mix, nor did they induce a significant increase of the micronuclei in erythrocytes. Taking the high correlation between mutagenicity and carcinogenicity into consideration, these results suggest that the fasciolicides tested in this investigation are devoid of carcinogenic action.

Animals↗
PubMed1985

Cystinosis with marked atrophy of the kidneys and thyroid. Histological and ultrastructural studies in an autopsy case.

The eldest autopsied case (a 23-year-old man) of infantile form of cystinosis with uremia and myxoedema was reported. The cystine content per gram wet tissue of various organs was arranged as follows: the thyroid (4.61 mg), kidney (1.71 mg), eye (0.75 mg), spleen (0.65 mg), liver (0.49 mg), and brain (0.016 mg). In polarized light microscopy, cystine crystals were detected in the epithelial cells and epithelial lumina of both kidneys by Wollaston test, and foam cells with cystine crystals were histologically found in the reticuloendothelial and other organs, especially in the bone marrows. Moreover, electron microscopic findings revealed square, rectangular or lozenge-shaped small cystine crystal profiles in osmophilic dense bodies of the histiocytic cells and in the cytoplasm of the foam cells. In some of them, positive reaction for acid phosphatase activity was specifically localized at the periphery of the cystine crystal profiles.

Adult↗
PubMed1985

Plasmid-cured Salmonella enteritidis AL1192 as a candidate for a live vaccine.

We report the immunizing capacity of Salmonella enteritidis AL1192, a strain that has been cured of a 36-megadalton plasmid, to protect ddY mice against subsequent challenge with virulent salmonellas. This strain, which was given subcutaneously at a dose of 10(6) organisms, provided significant protection against oral, subcutaneous, or intraperitoneal challenge by virulent wild-type strains of not only S. enteritidis, but also S. dublin, S. naestved, and S. typhimurium.

Animals↗
PubMed1984

Effects of aminobenzyl penicillin (AB-PC), methylchlorophenyl isoxazolyl penicillin (MCI-PC) and 6-aminopenicillanic acid (6-APA) on the contractile response of guinea-pig urinary bladder.

The present study was undertaken to investigate the effects of aminobenzyl penicillin (AB-PC), methylchlorophenyl isoxazolyl penicillin (MCI-PC), and 6-aminopenicillanic acid (6-APA) on the contractile response of guinea-pig urinary bladder. AB-PC, MCI-PC, and 6-APA, respectively, diminished the intramural electrical stimulation-induced contractile response. AB-PC had almost no effect on the contractile response to exogenous acetylcholine, while MCI-PC remarkably reduced it. The reducing effect of MCI-PC was greater on the intramural electrical stimulation-induced contractile response than it is on the exogenous acetylcholine-induced contractile response. 6-APA slightly reduced the exogenous acetylcholine-induced contractile response. The reducing effect of 6-APA was a little weaker on the exogenous acetylcholine-induced contractile response than it is on the intramural electrical stimulation-induced contractile response. By the addition of AB-PC, the amplitude of spontaneous contractile response of the tissue was reduced gradually with light lowering of the tonus level of the tissue was almost prevented with a little lowering of the tonus level of the tissue. The effects of AB-PC and MCI-PC on the spontaneous contractile response of the tissue mentioned above were also observed in the presence of tetrodotoxin. On the other hand, by the addition of 6-APA, the reducing effect on the amplitude of spontaneous contractile response of the tissue and increasing effect on its frequency were recognized with remarkable raise of the tonus level of the tissue. These phenomena which were induced by 6-APA were also observed in the presence of tetrodotoxin. From these results, the conclusion comes as follows: 1) AB-PC may affect not only on the muscle but also on the intramural cholinergic nerves. 2) MCI-PC may affect on the muscle, but its effect on the intramural nerves is also not likely to be negligible at this time. 3) 6-APA may affect mainly on the muscle.

Acetylcholine↗
PubMed1984

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miokamycin). Part I-1. Acute toxicity in mice.

Miokamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens. The objective of this study was to determine the acute toxicity of MOM, non-crystalline solid, in male and female mice (Jcl-ICR, SPF, 5-week-old) after single i.p., and p.o. administration of this material at a dose level of 5,000 mg/kg as the maximum physically applicable dose. MOM, non-crystalline solid, exhibited no acute toxicity in the present study. LD0 values were estimated as more than 5,000 mg/kg in each route of administration.

Animals↗
PubMed1984

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miokamycin). Part I-2. Acute toxicity in rats.

Miokamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens. The object of this study was to determine the acute toxicity in male and female rats (Wistar, 5-week-old) after single i.p., s.c. and p.o. administration of MOM, non-crystalline solid, at a dose level of 5,000 mg/kg as the maximum physically applicable dose. Observations were kept for 1 week after administration. In conclusion, no animal died during an observation period for 1 week so that the LD0 values were estimated to be more than 5,000 mg/kg in all routes of administration.

Animals↗
PubMed1984

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miokamycin). Part II-1. Subacute toxicity in rats.

Miokamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens. The objective of this study was to determine the subacute toxicity in male and female rats (Wistar, SPF, 5-week-old) after repeated oral administration of MOM, non-crystalline solid, for 5 weeks at selected dosage levels of 1,000, 2,000 and 4,000 mg/kg/day. It is concluded that the maximum non-toxic dosage level of MOM, non-crystalline solid, was 1,000 mg/kg/day but without specific toxic effects with rats when it was orally administered once daily for 5 weeks.

Administration, Oral↗
PubMed1984

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miokamycin). Part III-1. Chronic toxicity in rats.

Miokamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens. The objective of this study was to determine the chronic toxicity of MOM in male and female rats (Wistar, SPF, 5-week-old) after repeated oral administration of MOM, non-crystalline solid, for 26 weeks at daily dosages of 62.5, 125, 250, 500 and 1,000 mg/kg. The lowest dosage level of 62.5 mg/kg/day was only applied for female rats. In conclusion, the maximum non-toxic dosage level of MOM, non-crystalline solid, is presumed to be 250 mg/kg in male and female rats with p.o. administered once daily for 26 weeks.

Administration, Oral↗
PubMed1984

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-1. Toxicity of metabolites of miocamycin: acute toxicity of Mb1 in mice.

Miocamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens. MOM is metabolized into 4 main metabolites of Mb1, Mb2, Mb6 and Mb12. The object of this study was to evaluate acute toxicity in male and female mice after single oral administration of Mb1, a metabolite of MOM, at a dose level of 5,000 mg/kg as the maximum physically applicable dose. Observations were kept for 1 week after administration. In conclusion, Mb1 exhibited no acute toxicity in present study. The LD0 values were estimated as more than 5,000 mg/kg.

Administration, Oral↗
PubMed1984

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-2. Toxicity of metabolites of miocamycin: acute toxicity of Mb1 in rats.

Acute toxicity studies on miocamycin (MOM), non-crystalline solid, and its metabolite Mb1 were performed in mice in the previous studies. In the present studies, we evaluated acute toxicity of Mb1 in male and female rats after single oral administration at the maximum physically applicable dose of 5,000 mg/kg. Observations were continued for 1 week after treatment. It is concluded that LD0 values of Mb1 were estimated more than 5,000 mg/kg.

Animals↗
PubMed1984

Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-3. Toxicity of metabolites of miocamycin: subacute toxicity of Mb1 in rats.

Miocamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic and is metabolized into 4 main metabolites of Mb1, Mb2, Mb6 and Mb12. In the previous study, LD0 values of Mb1 were estimated more than 5,000 mg/kg in male and female rats as Mb1 did not exhibited any lethal toxicity even at the maximum physically applicable dose of 5,000 mg/kg. The object of this study was to examine subacute toxicity in male and female rats after repeated p.o. administration of Mb1 for 5 weeks at a daily dosage of 125, 250, 500 and 1,000 mg/kg. It is concluded that no manifest toxicity was observed in this subacute toxicity study on Mb1 in rats.

Animals↗